Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.83, $0.01 better than the analyst estimate of $1.82. Revenue for the quarter came in at $12 billion versus the consensus estimate of $12.12 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2022 EPS of $7.65-$7.95.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.